U.S. Mulls Registration Fees For Foreign Drug Manufacturers
This article was originally published in PharmAsia News
In light of recent safety concerns about foreign-manufactured pharmaceutical products, members of the U.S. Congress are considering whether to introduce registration fees for foreign drug manufacturers exporting products to the U.S
You may also be interested in...
U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant
Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).